Literature DB >> 28609681

Epigenetic modulation in cancer immunotherapy.

Stuart J Gallagher1, Elena Shklovskaya2, Peter Hersey2.   

Abstract

The success of immune checkpoint inhibitors in cancer immunotherapy has been widely heralded. However many cancer patients do not respond to immune checkpoint therapy and some relapse due to acquired tumor resistance. Epigenetic targeting may be beneficial in cancer immunotherapy by reversing immune avoidance and escape mechanisms employed by cancer cells, as well as by modulating immune cell differentiation and function. In this manuscript we review recent findings suggesting how epigenetics may be used to improve cancer immunotherapy. We focus on the inhibitors of the CTLA4 and PD1 immune checkpoints and epigenetic modifiers of histone acetylation and methylation and DNA methylation.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28609681     DOI： 10.1016/j.coph.2017.05.006

Source DB:  PubMed          Journal:  Curr Opin Pharmacol        ISSN： 1471-4892            Impact factor:   5.547


  20 in total

Review 1.  Epidrugs: targeting epigenetic marks in cancer treatment.

Authors:  Cristiana Libardi Miranda Furtado; Maria Claudia Dos Santos Luciano; Renan Da Silva Santos; Gilvan Pessoa Furtado; Manoel Odorico Moraes; Claudia Pessoa
Journal:  Epigenetics       Date:  2019-07-13       Impact factor: 4.528

Review 2.  The role of epigenetic modifications in drug resistance and treatment of breast cancer.

Authors:  Mohsen Karami Fath; Ali Azargoonjahromi; Arash Kiani; Fateme Jalalifar; Parisa Osati; Mahsa Akbari Oryani; Fateh Shakeri; Farhad Nasirzadeh; Behman Khalesi; Mohsen Nabi-Afjadi; Hamidreza Zalpoor; Maysam Mard-Soltani; Zahra Payandeh
Journal:  Cell Mol Biol Lett       Date:  2022-06-28       Impact factor: 8.702

Review 3.  Targeting the epigenetic regulation of antitumour immunity.

Authors:  Simon J Hogg; Paul A Beavis; Mark A Dawson; Ricky W Johnstone
Journal:  Nat Rev Drug Discov       Date:  2020-09-14       Impact factor: 84.694

Review 4.  Acquired resistance to cancer immunotherapy.

Authors:  Arianna Draghi; Christopher Aled Chamberlain; Andrew Furness; Marco Donia
Journal:  Semin Immunopathol       Date:  2018-07-02       Impact factor: 9.623

Review 5.  Epigenetics of Most Aggressive Solid Tumors: Pathways, Targets and Treatments.

Authors:  Javier Martinez-Useros; Mario Martin-Galan; Maria Florez-Cespedes; Jesus Garcia-Foncillas
Journal:  Cancers (Basel)       Date:  2021-06-27       Impact factor: 6.639

Review 6.  Zebrafish Xenograft: An Evolutionary Experiment in Tumour Biology.

Authors:  Rachael A Wyatt; Nhu P V Trieu; Bryan D Crawford
Journal:  Genes (Basel)       Date:  2017-09-05       Impact factor: 4.096

Review 7.  Potential Epigenetic-Based Therapeutic Targets for Glioma.

Authors:  Lanlan Zang; Shukkoor Muhammed Kondengaden; Fengyuan Che; Lijuan Wang; Xueyuan Heng
Journal:  Front Mol Neurosci       Date:  2018-11-15       Impact factor: 5.639

8.  DNA methylation and repressive H3K9 and H3K27 trimethylation in the promoter regions of PD-1, CTLA-4, TIM-3, LAG-3, TIGIT, and PD-L1 genes in human primary breast cancer.

Authors:  Varun Sasidharan Nair; Haytham El Salhat; Rowaida Z Taha; Anne John; Bassam R Ali; Eyad Elkord
Journal:  Clin Epigenetics       Date:  2018-06-15       Impact factor: 6.551

Review 9.  Epigenetic Regulation in Sepsis, Role in Pathophysiology and Therapeutic Perspective.

Authors:  Renata Brito Falcão-Holanda; Milena Karina Colo Brunialti; Miriam Galvonas Jasiulionis; Reinaldo Salomão
Journal:  Front Med (Lausanne)       Date:  2021-07-12

Review 10.  Role of Epigenetic Modifications in Inhibitory Immune Checkpoints in Cancer Development and Progression.

Authors:  Reem Saleh; Salman M Toor; Varun Sasidharan Nair; Eyad Elkord
Journal:  Front Immunol       Date:  2020-07-14       Impact factor: 7.561
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.